The pharmaceutical giant reaffirmed the modest 2026 outlook that rattled investors in December.

Pfizer (PFE) delivered earnings and revenue surprises of +16.81% and +4.26%, respectively, for the quarter ended December ...

PFE, has entered a global licensing agreement with Novavax to use Matrix-M adjuvant technology in the development of up to ...

“Pfizer appears cheap with a near 7% yield, but capital allocation constraints undermine its investment case. Nearly all of ...

Management indicated full year revenue is expected to align with broader market expectations Non GAAP earnings per share ...

To help answer common vaccine questions, we consulted Dr. Stanley Perlman, a professor at the University of Iowa’s Carver ...

Pfizer crushed Q2 estimates with $14.7B revenue and $0.78 EPS, signaling a powerful turnaround driven by broad-based growth and operational excellence. A successful cost realignment program drove the ...

Pfizer CEO Albert Bourla said the company was on track with new products, but shares fell as it signaled lower revenues in 2026 ...